Table 1 |
||||
|
Characteristics of patients and controls. |
||||
|
Characteristics |
Number (%) or mean (range) |
|||
|
|
||||
|
HC (n = 30) |
AAV |
|||
|
|
||||
|
Remission (n = 37) |
Activea (n = 5) |
Activeb (n = 18) |
||
|
|
||||
|
Male |
17 (57) |
25 (68) |
3 (60) |
14 (78) |
|
Age (years) |
45 (28-64) |
57 (26-84) |
58 (47-68) |
58 (32-81) |
|
Diagnosis |
||||
|
GPA |
26 |
4 |
13 |
|
|
MPA |
9 |
1 |
5 |
|
|
NCGN |
2 |
0 |
0 |
|
|
ANCA-specificity |
||||
|
PR3 |
24 (65) |
4 (80) |
13 (72) |
|
|
MPO |
13 (35) |
1 (20) |
5 (28) |
|
|
Organ involvement |
||||
|
ENT |
0 |
4 (80) |
5 (28) |
|
|
Eye |
0 |
1 (20) |
4 (22) |
|
|
Lung |
0 |
4 (80) |
8 (44) |
|
|
Kidney |
0 |
2 (40) |
13 (72) |
|
|
Skin |
0 |
1 (20) |
0 |
|
|
Nervous system |
0 |
1 (20) |
2 (11) |
|
|
BVAS, median (range) |
0 |
14.8 (6-26) |
17.5 (6-33) |
|
|
Treatment |
||||
|
MMF |
0 |
1 (20) |
3 (17) |
|
|
CYC |
0 |
4 (80) |
11 (61) |
|
|
Prednisolon |
0 |
4 (80) |
16 (89) |
|
|
|
||||
|
AAV, ANCA-associated vasculitides; ANCA, anti-neutrophil cytoplasmic autoantibody; BVAS, Birmingham Vasculitis Activity Score; CYC, cyclophosphamide; ENT, ear, nose and throat; GPA, granulomatosis with polyangiitis; HC, healthy control; MMF, mycophenolate mophetil; MPA, microscopic polyangiitis; MPO, myeloperoxidase; NCGN, necrotizing crescentic glomerulonephritis; PR3, proteinase 3; aActive patients included in CXCR1 and CXCR2 measurement by flow cytometry. bActive patients included in cytokine profiling by ELISA. |
||||
|
Hu et al. Arthritis Research & Therapy 2011 13:R201 doi:10.1186/ar3534 |
||||
